Hepion Pharmaceuticals, Inc. (HEPA)
NASDAQ: HEPA · Real-Time Price · USD
0.2875
-0.0025 (-0.86%)
At close: Apr 25, 2025, 4:00 PM
0.2875
0.00 (0.00%)
Pre-market: Apr 28, 2025, 6:41 AM EDT
Hepion Pharmaceuticals Employees
Hepion Pharmaceuticals had 22 employees as of December 31, 2023. The number of employees decreased by 3 or -12.00% compared to the previous year.
Employees
22
Change (1Y)
-3
Growth (1Y)
-12.00%
Revenue / Employee
n/a
Profits / Employee
-$599,655
Market Cap
3.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
HEPA News
- 6 weeks ago - Hepion Pharmaceuticals Announces Reverse Stock Split - GlobeNewsWire
- 4 months ago - Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - GlobeNewsWire
- 5 months ago - Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson's Disease Study Group - GlobeNewsWire
- 5 months ago - Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - GlobeNewsWire
- 8 months ago - Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - GlobeNewsWire
- 9 months ago - Fatty-Liver Focused Hepion Pharmaceuticals Agrees To Merge With Israel-Based Parkinson's Disease Drug Developer - Benzinga
- 1 year ago - Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH' Trial - GlobeNewsWire
- 1 year ago - Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell - GlobeNewsWire